U.S. Senate reauthorizes FDA to collect fees from drugmakers



(Reuters) – The U.S. Senate on Thursday passed a bill allowing the Food and Drug Administration to continue collecting fees from drug companies to review new product applications.

The FDA Reauthorization Act renews an existing law that expires on Sept. 30 and which provides the majority of FDA funds used to review pharmaceuticals and determine whether they are safe and effective. The Senate passed the bill by a vote of 94-1.

It was passed last month in the House of Representatives.

Separately, the Senate passed a so-called right-to-try bill designed to allow terminally ill patients access to unapproved medications and to provide immunity for physicians willing to administer the treatments. The House has not yet passed that bill.

Reporting by Toni Clarke in Washington; Editing by Paul Simao


Source link


Articles You May Like

India battles record COVID surge as rallies, Hindu festival draw huge crowds
Commentary: If true, leaked conversation between Anwar and Zahid reveal backroom dealing
The true cost of the demand for cheap clothes, to you and the environment
Pakistan bans Islamist political party after violent rallies
Thailand reports record new COVID-19 cases for second consecutive day

Leave a Reply

Your email address will not be published. Required fields are marked *